Comparing Anika Therapeutics (NASDAQ:ANIK) & Entera Bio (NASDAQ:ENTX)

Entera Bio (NASDAQ:ENTX) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Entera Bio and Anika Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1	0	1	0	2.00
Anika Therapeutics	1	0	2	1	2.75

Entera Bio presently has a consensus price target of $9.00, indicating a potential upside of 204.05%. Anika Therapeutics has a consensus price target of $21.00, indicating a potential upside of 0.77%. Given Entera Bio’s higher possible upside, equities research analysts plainly believe Entera Bio is more favorable than Anika Therapeutics.

Risk & Volatility

Entera Bio has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500.

Profitability

This table compares Entera Bio and Anika Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Anika Therapeutics	-3.14%	0.20%	0.15%

Insider and Institutional Ownership

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Entera Bio and Anika Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40,000.00	12,863.42	-$11.44 million	($0.35)	-8.46
Anika Therapeutics	$112.82 million	2.47	-$10.88 million	($0.27)	-77.19

Anika Therapeutics has higher revenue and earnings than Entera Bio. Anika Therapeutics is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Anika Therapeutics beats Entera Bio on 10 of the 15 factors compared between the two stocks.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

About Anika Therapeutics

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company’s joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.